Navigation Links
Catalent Expert to Discuss the Importance of Formulation to Benefit Diabetes Patients at NLS Days
Date:9/4/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming Nordic Life Science Days (NLS Days) conference, being held at the MalmöMässan Exhibition & Congress Center, Malmö, Sweden on Sept. 10-12, 2019.

On Thursday, Sept. 12 at 8:45 a.m., Dr. Harris will participate in the “Digitalization for the Benefit of the Diabetes Patient” panel session. The panelists will present different perspectives of how diabetes patients can benefit from recent digital advancements including viewpoints from the pharmaceutical industry, digitalization experts, and patient support groups. Dr. Harris will discuss the importance of formulation to overcome drug factors such as poor solubility and patient factors, including pill fatigue from the burden of multiple daily doses. He will also explain ways in which formulators can work with device developers on complex drug products to improve patient outcomes.

Ahead of NLS Days, on Tuesday, Sept. 10, Catalent will host a workshop, titled “Setting up your Drug for Clinical Success: Strategies and Considerations from Discovery to Clinic”. The day-long event will include expert speakers from Catalent and the wider pharmaceutical industry, and will focus on the key considerations for transitioning a molecule from discovery through to clinical studies. For more information, please visit: catalentmalmo.com.

Dr. Harris has over 35 years’ experience in the pharmaceutical industry. He started his career in technical support roles with R.P. Scherer, Warner Lambert and Glaxo Wellcome, before spending time in academia as a Research Fellow at the University of Manchester. For the past 15 years, Dr. Harris has worked in the pharmaceutical contract development and manufacturing sector, holding senior technical roles with Quay Pharma, Capsugel, Penn Pharma and Juniper Pharma Services (now part of Catalent). He has overseen the development of numerous new drug candidates for clinical evaluation and maintains a keen interest in technologies for enhancing oral bioavailability for challenging compounds, and the development of pediatric medicines.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard(at)nepr(dot)agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 30 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_expert_to_discuss_the_importance_of_formulation_to_benefit_diabetes_patients_at_nls_days/prweb16543980.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
2. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
3. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
4. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
5. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
6. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
7. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
8. Cold Chain Experts Modality Solutions Recognized as an Inc. Verified Company
9. Lauren Bronich-Hall, Senior Quality Management Expert, Joins NDA Partners as an Expert Consultant
10. Process Characterization Expert Dr. Philippe Cini to Moderate Session at ISPE
11. October is Non-GMO Month – Industry Expert David Carter Available for Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... , ... September 17, 2019 , ... Tucker, a Labrador ... only four months old, Tucker was limping and lame on his right hip and ... dysplasia and it was called “the worst case the vet had seen.” He was ...
(Date:9/17/2019)... ... September 16, 2019 , ... ... with the China Focus @ Biotech Week Boston, a forum organized by MyBioGate, ... in healthcare innovation. , After a careful process of evaluation, twelve companies out ...
(Date:9/9/2019)... ... September 09, 2019 , ... Visikol CEO Dr. Michael Johnson ... focused on how best to characterize 3D cell culture models. The inherent problem of ... too thick and opaque to image through and therefore traditional wide-field or even confocal ...
(Date:8/29/2019)... ROCHESTER, N.Y. (PRWEB) , ... August 29, 2019 ... ... within a chronic disease affecting grapevines, a feat they hope will ultimately help ... products. , Researchers including several Rochester Institute of Technology faculty and alumni sequenced ...
Breaking Biology Technology:
(Date:8/27/2019)... ... August 26, 2019 , ... Shoreline Biome , ... strain level, has hired Bill McKenzie as its CEO and Karen Woodward as its ... Shoreline Biome meet growing demand for its products and expand the company’s sales worldwide. ...
(Date:8/27/2019)... ... August 27, 2019 , ... Ambry Genetics ... improve genetic testing guidelines. In the largest cohort study of its kind, Ambry ... at-risk patients. , Clinicians use guidelines to inform decisions about which patients ...
(Date:8/25/2019)... ... 2019 , ... Sierra Instruments is pleased to announce that their redesigned website ... live. Sierra has redesigned entry to the site with both engineers and those new ... to navigate with streamlined menus and simple access to resources and information on products ...
Breaking Biology News(10 mins):